



MSN Laboratories Private Limited  
R&D Center, Formulation Division.

### SAFETY DATA SHEET

Product Name	DEFERASIROX ORAL GRANULES 90 mg, 180 mg & 360 mg	Page 1 of 4
--------------	--	-------------

#### 1. Product Information

**Product Name:** Deferasirox Oral Granules 90 mg, 180 mg & 360 mg

#### 2. Composition/Information on Ingredients

C.A.S. No : 201530-41-8  
Molecular Formula :  $C_{21}H_{15}N_3O_4$   
Molecular Weight : 373.4  
Chemical Name : 4-[3,5-Bis (2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-benzoic acid.

#### 3. Hazards Identification

##### Potential Health Effects

The toxicological properties of this material have not been investigated. Use appropriate procedures to prevent opportunities for direct contact with the skin or eyes and to prevent inhalation. Compound is Non-hazardous, Non-Toxic/Non-Flammable.

#### 4. First Aid Measures

##### Eyes:

Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids.

##### Skin:

Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.

##### Ingestion:

Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.

##### Inhalation:

Remove from exposure and move to fresh air immediately.

#### 5. Emergency Overview

**Major Health Hazards:** No major health hazards are known.

**D-Block MASTER**



MSN Laboratories Private Limited  
R&D Center, Formulation Division.

## SAFETY DATA SHEET

Product Name

DEFERASIROX ORAL GRANULES 90 mg, 180 mg & 360 mg

Page 2 of 4

### 6. Fire Fighting Measures

#### General Information:

As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.

#### Extinguishing Media:

In case of fire, use water, dry chemical, chemical foam, or alcohol-resistant foam.

### 7. Accidental Release Measures

General Information: Use proper personal protective equipment as indicated in Section 8.

#### Spills/Leaks:

Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up, then place into a suitable container for disposal.

### 8. Handling and Storage

#### Handling:

Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Avoid contact with eyes, skin, and clothing. Avoid ingestion and inhalation.

**Storage Conditions:** Store as directed by product packaging.

### 9. Exposure Controls/Personal Protection

Personal protective equipment as follows:

- **Breathing equipment:** NIOSH/MSHA-approved respirator.
- **Protection of hands:** chemical-resistant rubber gloves.
- **Eye protection:** chemical safety goggles.

### 10. Physical and Chemical Properties

**Appearance:** White to almost white granules in a sachet

### 11. Stability and Reactivity

#### Chemical Stability:

Stable under normal temperatures and pressures.

#### Conditions to Avoid:

FDCA CONTROLLED COPY

D-Block MASTER



MSN Laboratories Private Limited  
R&D Center, Formulation Division.

### SAFETY DATA SHEET

Product Name | DEFERASIROX ORAL GRANULES 90 mg, 180 mg & 360 mg

Page 3 of 4

Incompatible materials, strong oxidants.

Incompatibilities with Other Materials:

Strong oxidizing agents, strong bases.

Hazardous Decomposition Products:

Nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide, nitrogen.

Hazardous Polymerization: Has not been reported.

### 12. Toxicological Information

RTECS#:

CAS#: LD50/LC50:

CAS#: Draize test, rabbit, eye: 100 mg/24H Moderate; Oral,

mouse: LD50 = 300 mg/kg; Oral, rabbit: LD50 = 3200 mg/kg; Oral, rat:

LD50 = 980 mg/kg.

Carcinogenicity:

Salicylamide -

Not listed by ACGIH, IARC, NIOSH, NTP, or OSHA.

See actual entry in RTECS for complete information.

### 13. Disposal Considerations

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and waste water.

### 14. Transport Information

IATA : No information available.

IMO : No information available.

ID/ADR : No information available.

**D-Block MASTER**

EDQA CONTROLLED COPY



MSN Laboratories Private Limited  
R&D Center, Formulation Division.

### SAFETY DATA SHEET

Product Name

DEFERASIROX ORAL GRANULES 90 mg, 180 mg & 360 mg

Page 4 of 4

#### 15. Regulatory Information

- European/International Regulations
- European Labeling in Accordance with EC Directives
- Hazard Symbols: XN
- Risk Phrases:
  - R 22 Harmful if swallowed.
- Safety Phrases:
  - WGK (Water Danger/Protection)
- CAS# United Kingdom Occupational Exposure Limits
- United Kingdom Maximum Exposure Limits
- Canada
  - CAS# is listed on Canada's DSL List.
  - CAS# is not listed on Canada's Ingredient Disclosure List.
- Exposure Limits
- US FEDERAL
- TSCA
  - CAS# is listed on the TSCA inventory

#### 16. Other Information

While the information herein is believed to be reliable, it is furnished without warranty of any kind. It shall be used only as a guide. We assume no liabilities from the use of this product or information contained herein.

**D-Block MASTER**

FDQA CONTROLLED COPY